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X-linked myopathy with postural muscle atrophy
(XMPMA) is a recently described myopathy; it
may cause symptomatic sleep disordered breath-
ing which can be managed with non-invasive
ventilation.
Introduction
Many myopathies involve the respiratory muscles,
both inspiratory and expiratory muscle groups.
Inspiratory muscle weakness results in problems
ranging from mild dyspnoea, orthopnoea, sleep-
disordered breathing and nocturnal hypoventilation
through to diurnal ventilatory failure. Expiratory
muscle weakness manifests with poor cough and
airway clearance resulting in difﬁculty with
secretion management and respiratory tract infec-
tions. Respiratory complications are the major
cause of morbidity and mortality in many progress-
ive neuromuscular disorders.
1
The beneﬁt of long-term non-invasive venti-
lation (NIV) on both symptoms and survival
across a range of causes of chronic respiratory
failure is well established.
2 The provision of this
service has led to close links between respiratory
medicine and neurology departments and the
need for respiratory physicians to remain up to
date with the expanding number of disorders
that are covered by the label ‘muscular
dystrophies’.
Here we present the ﬁrst reported case of the
need for long-term nocturnal NIV in a patient
with XMPMA. This disorder has only been ident-
iﬁed recently and there remain just a handful of
families worldwide diagnosed with this type of
myopathy.
Case report
A 58-year-old man was admitted acutely unwell to
his local hospital Emergency Department. In the
preceding weeks he had become bed-bound due
to progressive weakness, increasingly breathless
at rest and described clear orthopnoea. His con-
centration was poor and in the days immediately
before admission family members reported exces-
sive daytime sleepiness and hallucinations. Blood
tests were unremarkable and chest radiograph
showed small lung volumes with no evidence of
consolidation. An arterial blood gas revealed
acute on chronic ventilatory failure (pH 7.18,
pCO2 16.3 kPa, pO2 10.5 kPa and serum bicarbon-
ate 44 mmol/L). He was established on to NIV
acutely and when stable transferred to our
regional long-term ventilation service.
He had ﬁrst presented to medical services over
25 years previously due to mild lower limb weak-
ness and moderately elevated serum creatine
kinase. Despite extensive tests including nerve
conduction studies, electromyography and
muscle biopsy, no diagnosis was reached though
the label ‘muscular dystrophy’ was later given in
clinic letters. His symptoms progressed slowly
and he declined regular clinic appointments.
Three years before this admission he had been
diagnosed with XMPMA. A male family
member had been diagnosed with the disease at
a specialist neuromuscular centre and the patient
attended there for review. Causative mutation in
the four and a half LIM domain gene (FHL1) on
the X chromosome was conﬁrmed. At that time
he was still mobile with crutches, had no symp-
toms of nocturnal hypoventilation and a sitting
vital capacity of 2.43 L (63% predicted) with no
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1signiﬁcant fall when supine. He was not seen
again by secondary care services until this admis-
sion to his local acute hospital.
Clinical examination showed clear paradoxical
abdominal breathing, vital capacity was 0.83 L
and maximal inspiratory pressures were reduced
consistent with diaphragm weakness (<30
cmH2O). He was established on long-term noctur-
nal NIV via a face mask with 1 L oxygen
entrained. Arterial blood gas taken in the
morning prior to discharge was much improved
(pH 7.41, pCO2 6.1 kPa, serum bicarbonate
26.7 mmol/L) and overnight oximetry conﬁrmed
that less than 30 min spent with saturation <90%
as is our local protocol.
Cough peak ﬂow was low (<100 L/min) and
maximal expiratory pressures were consistent
with expiratory muscle weakness. He required
one course of intravenous antibiotic for hospital
acquired pneumonia and had been issued with a
cough-assist machine on discharge.
When most recently seen in clinic by our phy-
siotherapy team he had remained well with no
symptoms suggestive of inadequate ventilation
and good compliance with NIV.
Discussion
Myopathies are muscle disorders typiﬁed by
weakness and atrophy of skeletal muscle. Many
will involve both respiratory and cardiac muscle
though the degree is variable between and
within individual disorders. Several myopathies
have an X-linked recessive mode of genetic
transmission, the most common is Duchenne mus-
cular dystrophy, and others include Becker
muscular dystrophy and Emery Dreifuss muscu-
lar dystrophy.
3
A new and phenotypically distinct late onset
X-linked myopathy, named X-linked myopathy
with postural muscle atrophy (XMPMA) was
described in 2008 after genetic study of a large
Austrian family spanning several generations
which was affected by an uncharacterized myopa-
thy.
3 The main clinical features were atrophy of
some postural muscles combined with a general-
ized hypertrophy of others.
Linkage studies and haplotype analysis
suggested candidate genes and the four and a
half LIM domain gene (FHL1) at Xq26.3 was
identiﬁed as key. Further tests identiﬁed a mis-
sense mutation within the FHL1 gene with
marked decrease in expression of FHL1 protein
as responsible for this myopathy. FHL1 protein
was not reduced in either Becker muscular dystro-
phy of limb girdle muscular dystrophy. The exact
role of FHL1 is not known, it is more common in
oxidative muscle ﬁbres and is suggested to play
a role in sarcomere synthesis and assembly.
3,4
FHL1 is expressed in skeletal and cardiac
muscle. In the initial Austrian family the cause
of death was uncertain, many were diagnosed
with heart failure of unknown cause. In the
initial description a second family from the
United Kingdom was demonstrated to have
XMPMA and it was conﬁrmed by genetic
testing. Many of these were previously labeled
with Becker muscular dystrophy and documented
to have died from respiratory failure.
3 Our patient
had an echocardiogram which showed no signiﬁ-
cant structural, valvular or ventricular function
abnormalities.
Summary
XMPMA is a new and rare disorder, it is clear that
in addition to peripheral muscles it can affect both
inspiratory and expiratory respiratory muscles. If
signiﬁcant then it may present with ventilatory
failure and the symptoms and signs of nocturnal
hypoventilation and poor cough as it did in our
patient. These symptoms and disordered physi-
ology can be stabilized, controlled and reversed
by the use of NIV and cough-assist techniques as
you would expect from other neuromuscular con-
ditions.
1 The case presented here is the ﬁrst one
reported of XMPMA treated successfully with
NIV in the published literature.
We hope this report informs the general reader
about XMPMA and that it should join the ever-
growing list of neuromuscular conditions of
which a respiratory physician involved in long-
term ventilation should be aware. With an ident-
iﬁed genetic cause it is likely to become more
common in clinical practice as many patients
and families with a myopathy of uncertain cause
are reassessed. The basic principles of assessment
and treatment are as for all neuromuscular dis-
orders affecting respiratory muscles and it is
clear that NIV is an effective therapy.
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